FDMT Stock Analysis: Buy, Sell, or Hold?
FDMT - 4D Molecular Therapeutics, Inc. Common Stock
$11.30
-1.01 (-8.20%)
▼
5d:
-11.16%
30d:
+29.59%
90d:
+15.19%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 10, 2026
26d
Get Alerted When FDMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: FDMT is down 11.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: FDMT is down 11.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: FDMT is currently trading at $11.30, which is considered fair relative to its 30-day fair value range of $9.20 to $12.61.
Technical Outlook: Technically, FDMT is in a uptrend. The price is currently testing key support at $11.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $28.22 (+149.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FDMT is in a uptrend. The price is currently testing key support at $11.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $28.22 (+149.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.20 -
$12.61
Company Quality Score
56/100
(HOLD)
Options IV Signal
1th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 1th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.2%)
- BULLISH: Trading 149.8% below Wall St target ($28.22)
- WARNING: Recommendation downgraded due to -11.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$9.20 -
$12.61
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.90
(16.8%)
Support & Resistance Levels
Support Level
$11.45
Resistance Level
$14.00
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.03
Wall Street Target
$28.22
(+149.8%)
Revenue Growth (YoY)
21664.3%
Profit Margin
-182.3%
Share & Embed Analysis
Last updated: July 13, 2026 11:31 PM ET
Data refreshes hourly during market hours. Next update: 12:31 AM
Data refreshes hourly during market hours. Next update: 12:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FDMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Ashoo Gupta
SELL
390 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
